This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MRTX Mirati Therapeutics (MRTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Mirati Therapeutics Stock (NASDAQ:MRTX) 30 days 90 days 365 days Advanced Chart Get Mirati Therapeutics alerts:Sign Up Key Stats Today's Range$58.70▼$58.7050-Day Range$58.70▼$59.2852-Week Range$27.30▼$64.41VolumeN/AAverage Volume2.76 million shsMarket Capitalization$4.12 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More… Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Stock News HeadlinesMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | markets.businessinsider.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJanuary 10, 2024 | finance.yahoo.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 27, 2025 | Altimetry (Ad)Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 25, 2023 | seekingalpha.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | reuters.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 22, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | msn.comMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesDecember 20, 2023 | finance.yahoo.comSee More Headlines MRTX Stock Analysis - Frequently Asked Questions How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.83) by $0.34. Mirati Therapeutics's revenue was up 203.7% compared to the same quarter last year. Does Mirati Therapeutics have any subsidiaries? Mirati Therapeutics subsidiaries include these companies: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V.. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirati Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH), Humana (HUM) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings11/06/2023Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRTX CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees587Year Founded2013Profitability EPS (Most Recent Fiscal Year)($12.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-740,870,000.00 Net Margins-1,900.65% Pretax Margin-1,899.99% Return on Equity-82.15% Return on Assets-67.82% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$12.44 million Price / Sales331.01 Cash FlowN/A Price / Cash FlowN/A Book Value$17.31 per share Price / Book3.39Miscellaneous Outstanding Shares70,150,000Free Float67,861,000Market Cap$4.12 billion OptionableOptionable Beta0.77 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:MRTX) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirati Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.